Steve Harr, CFO & Head, Corporate Development at Juno Therapeutics, Inc. (JUNO), sold 60,000 shares at $42.89 ($2.6M) on 2016-06-10, disclosed to the SEC on 2016-06-13.
Open-market sale of $2.6M JUNO by CFO & Head, Corporate Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.89 | 13,948 | $598K | 23.0% |
| 2 | $42.89 | 13,948 | $598K | 23.0% |
| 3 | $43.69 | 16,052 | $701K | 27.0% |
| 4 | $43.69 | 16,052 | $701K | 27.0% |
| Total | $43.32 avg | 60,000 | $2.6M | 100% |
| Filing → |
| JUNO | SELL | 2017-06-29 | $263K | — | Filing → |
| JUNO | SELL | 2016-03-04 | $225K | — | Filing → |
| JUNO | SELL | 2016-03-02 | $2.2M | — | Filing → |